Lamark Biotech raised ₹6.5 crore in a Pre-Series A funding round led by IAN Group to advance its thermostable insulin program and expand its biologics platform for enhanced global healthcare access.

Information on the Target

Lamark Biotech, an innovative biopharmaceutical startup based in Ahmedabad, has successfully raised ₹6.5 crore in a Pre-Series A funding round. This round was led by the IAN Group, which includes contributions from the IAN Alpha Fund, supported by BioAngels, as well as prominent domain experts Dr. Vinayender Tulla, Dr. Nita Roy, and Mr. Venkataraman KNK. Since its founding in 2018 by Dr. Vaibhav Bhatia, a trained biochemist and entrepreneur, Lamark Biotech has been focused on revolutionizing drug delivery methods for chronic diseases through its proprietary ProteoStrong™ platform. This innovative technology stabilizes fragile protein-based drugs such as insulin, antibodies, and enzymes without compromising their molecular integrity, effectively reducing reliance on cold-chain systems in drug distribution.

Dr. Vaibhav Bhatia, the Founder and CEO of Lamark Biotech, stated that this funding marks a critical turning point for the company and emphasizes their commitment to making high-efficacy biologics accessible globally. Lamark is particularly focused on accelerating its thermostable insulin program and expanding its platform to cover more essential therapeutics, ensuring that safe and effective treatments reach patients in need.

Industry Overview in India

The biopharmaceutical industry in India stands out for its significant potential and robust growth trajectory. Home to one of the largest pharmaceutical markets in the world, India is expected to reach $55 billion by 2025. The trend toward personalized medicine and biotechnology